In recent years, stem cells have generated much interest as a potential tool for pharmacological and toxicology screening (CIRM 2008; ABPI 2008) , due to various shortcomings of currently utilized assay models based on established cell lines, primary explanted somatic cells and laboratory animals Vinoth et al. 2008) . In vitro toxicology screening most commonly utilize established cell lines of cancerous/tumorigenic origin, that are highly adapted to in vitro culture conditions after countless passages, and which contain chromosomal and genetic aberrations that render them immortal (Phelps et al. 1996) . Such inherent deWciencies make them non-representative of how a normal cell behaves physiologically in vivo. Indeed, it is common knowledge that immortalized transformed cell lines are more robust, proliferates faster, and have much less fastidious nutritional requirements compared to primary somatic cells explanted from living tissues (Phelps et al. 1996) .
Hence it may be preferable to utilize primary explanted cultures of somatic cells for toxicology screening, but these often are heterogeneous cultures that display a high degree of inter-batch variability, making it challenging to obtain consistent and reproducible results in toxicology screening Vinoth et al. 2008) . Additionally, primary cell cultures of human origin often suVer from inconsistent availability, depending on the will of patients to donate. It is often the case that primary cultures are established from discarded human tissues of pathological origin, which would skew their response to toxic challenge. Moreover, one of the main logistical improvements realized in cellbased screening in recent years has been the introduction of batch-based cryopreserved cell preparations in high throughput screening, which have greatly improved reproducibility in assay performance (Zaman et al. 2007 ). However, due to a high degree of heterogeneity and interbatch variability in primary explanted somatic cells, these often display much inconsistency in their post freeze-thaw viability and metabolic activity unlike established cell lines (Zaman et al. 2007 ), which could further confound the reproducibility and accuracy of screening assays based on primary explanted somatic cells. The logistical challenges of high throughput cell based assays cannot be underestimated and the introduction of any new screening paradigms needs to be accompanied by robust and practical working practices, conditions that are diYcult to be met with primary explanted somatic cells.
Live animal models could provide yet another alternative for toxicology screening, but have a number of inherent Xaws. First, an animal model may not compare well with human physiology. Second, the use of live animals in routine toxicology screening of biomedical and cosmetic products may be ethically contentious, and can possibly aVect consumer conWdence. Last, live animals are expensive to purchase and maintain compared to in vitro cultured cells.
Stem cells utilized for toxicology screening can be of adult, fetal or embryonic origin (Weissman 2000; Zeng and Rao 2008) . Nevertheless, the ability of human embryonic stem cells (hESC) to be propagated indeWnitely within in vitro culture, oVers a distinct advantage over primary cultures of fetal and adult stem cells that would invariably become senescent after a limited number of passages ex vivo. Because hESC lines are theoretically 'immortal', provided that appropriate culture conditions for their propagation are continuously maintained (Skottman et al. 2007) , these can provide an almost limitless supply of cells from the same batch that would yield consistent and reproducible results in toxicology screening assays. The pluripotency of hESC provides yet another major advantage. Because diVerent somatic lineages would be expected to respond diVerently to the same toxic challenge, it may be necessary to screen more than one diVerentiated cell type in order to validate the safety of a particular substance that would come into direct contact with the human body. Whilst adult and fetal stem cells are highly restricted in their diVerentiation potential, the almost unrestricted ability of hESC to diVerentiate into any of the 200 or more somatic lineages within the human body (Ohtsuka and Dalton 2008) can potentially provide a multitude of diVerent cell types for toxicology screening.
Nevertheless, the application of hESC in experimental research and therapy (Mauron and Jaconi 2007; Waite and Nindl 2003) is fraught with ethical and moral controversy (Mauron and Jaconi 2007; Waite and Nindl 2003) , which in turn has sparked much heated debate and enactment of restrictive legislation in several countries (Childress 2004; Mertes et al. 2008) . The key issue of contention is the perception that human life begins at the onset of fertilization (Young 1994; Sullivan 2003) , so that the termination of embryos for the isolation of new hESC lines would represent wanton and willful destruction of human life (Araujo 2006) . The aim here is neither to dispute nor debate legal, ethical and moral issues pertaining to hESC research and application. Instead, the focus is on the sociological impact of utilizing hESC for toxicology screening of various biomedical and cosmetic products intended for human use. There is a risk that this might undermine consumer conWdence in a large segment of the population that hold a negative perception of hESC research. After all, it must be remembered that the marketability and commercial success of a product is ultimately dependent on consumer conWdence and goodwill. Prominent examples of products that have lost a signiWcant degree of consumer conWdence and goodwill as a result of vigorous campaigning and lobbying by a vocal minority include animal fur apparels (The Economist 2001), cosmetics that rely on animal testing (Kuehn 2003) , and food produced by factory-farming (Holdrege 2007) .
Recently, the successful reprogramming of adult somatic cells into an embryonic stem cell-like state through genetic manipulation (Yu et al. 2007; Takahashi et al. 2007 ), opens up a new opportunity for toxicology assay development that is free of ethical and moral controversy, unlike the derivation of hESC lines from human embryos. Two research groups, one in the USA (Yu et al. 2007 ) and the other in Japan (Takahashi et al. 2007) , achieved this breakthrough concurrently, even though there was some variation in their methodology. Whilst the study by Yu and colleagues in the USA (Yu et al. 2007 ) utilized lentiviral-mediated expression of four genes: Oct4, Sox2, Nanog, and Lin28; the study by Takahashi and colleagues in Japan (Takahashi et al. 2007 ) utilized retroviral transduction of Oct3/4, Sox2, Klf4, and c-Myc. The reprogrammed somatic cells, referred to as induced pluripotent stem cells (iPSC) possess characteristics that are very similar, if not identical to hESC (Yu et al. 2007; Takahashi et al. 2007 ). However, there are two major challenges faced in utilizing iPSC for toxicology screening assays.
First, it is currently unknown how the epigenetic state of reprogrammed iPSC actually compares with hESC derived from 'normal' human blastocyst-stage embryos (Surani et al. 2008; Han and Sidhu 2008) . There is a possibility that subtle diVerences in the epigenetic programming of iPSC and hESC might in turn lead to diVerences in their response to toxic challenge. This certainly requires further investigation. Presently, a commonly held view is that the epigenetic signature of hESC represents the 'gold standard' due to it's origin from normal human embryos; and that any diVerences in epigenetic programming of iPSC compared to hESC must therefore represent some form of aberration that would set it apart from normal cells. Nevertheless, this view is disputable because comparison of various hESC lines have in fact demonstrated much variability in epigenetic programming (Allegrucci and Young 2007; Rugg-Gunn et al. 2007) , and it is therefore uncertain which of these represent the correct 'gold standard' epigenetic signature that iPSC should ideally possess. Moreover, with the exception of embryotoxicity and teratogenicity testing, it is unlikely that toxicology screening will be carried out directly on undiVerentiated iPSC or hESC, but would instead utilize their diVerentiated somatic progenies. It that case, it may possibly be more advantageous to utilize iPSC rather than hESC, because iPSC being reprogrammed somatic cells, may more easily revert back to their original somatic epigenetic signature, whereas hESC lines do not have an original somatic epigenetic signature to revert back to. For example, if a particular toxicology assay would require mature skin epithelium, then it may be advantageous to utilize diVerentiated epithelial progenies of iPSC lines that were originally derived from skin, as it is speculated that the epigenetic signature of such cells would more closely resemble that of adult skin, as compared to hESCderived epithelial progenies. In the future, it is possible that iPSC lines for toxicology screening may also be derived from the reprogramming of primary explanted hepatocytes and cardiomyocytes, because such somatic lineages have wide-ranging applications in both toxicology and pharmacology screening.
Second, another major challenge is that the derivation of iPSC entails permanent genetic modiWcation to somatic cells, due to the use of viral transduction of recombinant DNA (Yu et al. 2007; Takahashi et al. 2007 ). Integration of recombinant DNA within the genome of iPSC lines might cause these cells or their diVerentiated progenies to behave diVerently from normal unmodiWed human cells, particularly when exposed to toxic challenge. Of particular concern is the possibility that the diVerentiated progenies of iPSC might acquire the 'cancer-like' properties of established cell lines, which would lessen their predicative value in toxicology screening. Indeed, previous human clinical trials on gene therapy have resulted in the development of cancer in the unfortunate patient (Hacein-Bey-Abina et al. 2008) , which has been blamed on mutagenesis induced by random insertion of recombinant DNA within the host genome. Nevertheless, there has recently been much progress in the development of new strategies for iPSC derivation that avoid integration of recombinant DNA within the host cell genome. These include the use of adenoviral vectors (Stadtfeld et al. 2008a) , plasmids (Okita et al. 2008) and small molecules involved in the wnt signaling pathway (Marson et al. 2008) . A more intriguing and novel alternative would be the direct delivery of transcription factors to the cytosol (Heng and Richards 2008; , either with protein transduction domains or immunoliposomes (Sullivan et al. 1986) , thus completely avoiding the use of recombinant DNA and genetic manipulation altogether. Although the delivered transcription factors will only have a limited active half-life in the cytosol, this is not implausible given that transgene expression is required only for the Wrst 10-12 days of the reprogramming process for iPSC derivation (Brambrink et al. 2008; Stadtfeld et al. 2008b) .
It is imperative that these two pertinent challenges be addressed prior to further research on the potential use of iPSC in toxicology screening. Because iPSC lines can be isolated from a diverse range of human individuals with well-characterized adult phenotypes, these can potentially provide a valuable tool for characterizing how variation in toxic susceptibility displayed by diVerent individuals correlates to their genetics, disease state and other observable phenotype. By contrast, such an opportunity does not exist with hESC lines because of the unknown and uncharacterized adult phenotype of pre-implantation embryos from which these cells are isolated. iPSC lines may also be created by reprogramming diseased human cells. DiseasespeciWc iPSC lines will be invaluable tools that allow scientists to watch the development of diseases in vitro, outside the patient's body. Indeed, iPSC lines representative of a variety of human genetic diseases such as Parkinson's disease, Down's syndrome and Type 1 diabetes mellitus have already been created (Park et al. 2008) . These cell lines represent an unprecedented opportunity to recapitulate both normal and pathological tissue formation in vitro, thereby facilitating drug development, toxicology screening, gene therapy and pathological investigation. Additionally, due to ethical and moral controversy surrounding the research and application of hESC lines, iPSC represent a much preferred alternative that is free of the political and legislative baggage accompanying hESC. Rapid progress and increasing scientiWc research in the iPSC Weld, together with the development of new technology platform give cause for optimism that the two major challenges discussed can be overcome in the near future.
